Rhumbline Advisers lifted its stake in Repligen Co. (NASDAQ:RGEN) by 15.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 102,734 shares of the biotechnology company’s stock after purchasing an additional 13,614 shares during the quarter. Rhumbline Advisers owned 0.24% of Repligen worth $3,727,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors also recently bought and sold shares of the company. First Manhattan Co. lifted its position in shares of Repligen by 16.7% in the fourth quarter. First Manhattan Co. now owns 10,500 shares of the biotechnology company’s stock worth $380,000 after purchasing an additional 1,500 shares in the last quarter. California Public Employees Retirement System lifted its position in shares of Repligen by 1.6% in the third quarter. California Public Employees Retirement System now owns 122,548 shares of the biotechnology company’s stock worth $4,696,000 after purchasing an additional 1,948 shares in the last quarter. Nationwide Fund Advisors lifted its position in shares of Repligen by 2.4% in the third quarter. Nationwide Fund Advisors now owns 84,480 shares of the biotechnology company’s stock worth $3,237,000 after purchasing an additional 1,979 shares in the last quarter. Swiss National Bank lifted its position in shares of Repligen by 5.3% in the fourth quarter. Swiss National Bank now owns 63,700 shares of the biotechnology company’s stock worth $2,311,000 after purchasing an additional 3,200 shares in the last quarter. Finally, American International Group Inc. lifted its position in shares of Repligen by 13.4% in the third quarter. American International Group Inc. now owns 29,476 shares of the biotechnology company’s stock worth $1,130,000 after purchasing an additional 3,479 shares in the last quarter. 87.60% of the stock is owned by institutional investors and hedge funds.
In related news, VP Howard Benjamin sold 12,729 shares of the stock in a transaction that occurred on Thursday, December 14th. The stock was sold at an average price of $35.34, for a total value of $449,842.86. Following the transaction, the vice president now owns 36,554 shares in the company, valued at $1,291,818.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Thomas F. Ryan, Jr. sold 4,696 shares of the stock in a transaction that occurred on Thursday, March 8th. The stock was sold at an average price of $36.16, for a total value of $169,807.36. Following the completion of the transaction, the director now owns 9,700 shares in the company, valued at approximately $350,752. The disclosure for this sale can be found here. Insiders sold 26,395 shares of company stock worth $942,122 in the last 90 days. 1.50% of the stock is currently owned by corporate insiders.
Repligen Co. (NASDAQ:RGEN) opened at $36.03 on Wednesday. Repligen Co. has a twelve month low of $29.56 and a twelve month high of $46.81. The company has a market capitalization of $1,624.54, a P/E ratio of 50.75, a P/E/G ratio of 2.51 and a beta of 0.94. The company has a quick ratio of 8.08, a current ratio of 9.63 and a debt-to-equity ratio of 0.17.
Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Thursday, February 22nd. The biotechnology company reported $0.20 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.08. Repligen had a return on equity of 7.08% and a net margin of 20.08%. The firm had revenue of $41.60 million for the quarter, compared to the consensus estimate of $41.13 million. During the same quarter in the prior year, the company posted $0.08 earnings per share. The firm’s revenue was up 62.5% on a year-over-year basis. analysts expect that Repligen Co. will post 0.7 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Repligen Co. (RGEN) Shares Bought by Rhumbline Advisers” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/03/14/repligen-co-rgen-shares-bought-by-rhumbline-advisers.html.
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.